Correction to: Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials.

Clin Pharmacokinet

Ultragenyx Pharmaceutical Inc., 60 Leveroni Court, Novato, CA, 94949, USA.

Published: May 2019

Introduction section, para 3, lines 2-4 which previously read.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828067	PMC
http://dx.doi.org/10.1007/s40262-018-0726-6	DOI Listing

Publication Analysis

correction pharmacokinetic

pharmacokinetic pharmacodynamic

pharmacodynamic modeling

modeling optimize

optimize dose

dose vestronidase

vestronidase alfa

alfa enzyme

enzyme replacement

replacement therapy

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!